Abstract
The reactive oxygen species (ROS) are known to be generated upon post‐ischemic reperfusion (I/R) of the heart, and to injure cardiac muscle cells. The hydrogen peroxide‐induced mortality of rat cardiomyoblasts H2c9 was markedly inhibited by previous administration with auto‐oxidation‐resistant pro‐vitamin C, the 2‐O‐phosphorylated derivative (Asc2P) of ascorbic acid (Asc). The cytoprotection was partially counteracted by an inhibitor of MAPK (mitogen‐activated protein kinase) kinase (MEK) as shown by DNA strand cleavage assay and mitochondrial dehydrogenase assay. Immunostains indicated that phosphorylated MAPK increased in the hydrogen peroxide‐treated cardiomyoblasts, and that this action was moderately inhibited by Asc2P and restored nearly to the initial, pretreatment level by combined administration of the MEK inhibitor and Asc2P. The I/R‐induced cell injuries in perfused rat hearts as estimated by extracellular release of the cardiac enzyme CPK were inhibited by 2‐O‐α‐glucosylascorbic acid (Asc2G) and Asc, whereas the observed cytoprotection for the cardiomyoblasts was partially counteracted by the MEK inhibitor. The increase in phosphorylated MAPK in I/R‐operated hearts was moderately inhibited by pro‐vitamin C, but restored nearly to the normal non‐operated level by combined administration with the MEK inhibitor. This is in contrast to no alteration in levels of non‐phosphorylated MAPK for all the cases examined as shown by Western blots, consistent with results of immunostains for the cardiomyoblasts. The inhibitory effect of the MEK inhibitor on MAPK phosphorylation was, therefore, suggested to counteract the cytoprotective effects of pro‐vitamin C via a thorough interruption of the phosphorylated MAPK signaling pathway. This was not true of ROS‐related events; the scavenging effects of Asc2G and Asc on hydroxyl radicals generated from I/R‐operated heart were not affected by combined administration with the MEK inhibitor, as shown by the spin‐trapping DMPO‐based ESR method. J. Cell. Biochem. 90: 219–226, 2003. © 2003 Wiley‐Liss, Inc.